Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome by unknown
ORIGINAL PAPER
Left cardiac sympathetic denervation for the management
of life-threatening ventricular tachyarrhythmias in young patients
with catecholaminergic polymorphic ventricular tachycardia
and long QT syndrome
Heike E. Schneider • Michael Steinmetz • Ulrich Krause •
Thomas Kriebel • Wolfgang Ruschewski • Thomas Paul
Received: 9 January 2012 / Accepted: 4 July 2012 / Published online: 21 July 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Background Left cardiac sympathetic denervation
(LCSD) may be a therapeutic adjunct for young patients
with catecholaminergic polymorphic ventricular tachycar-
dia (CPVT) and long QT syndrome (LQTS) who are not
fully protected by beta-blockade.
Objective The objective of this analysis was to report our
institutional experience with LSCD in young patients for
the management of life-threatening ventricular arrhythmias
in CPVT and LQTS.
Methods Ten young patients with CPVT and LQTS
underwent transaxillary LSCD at our institution. Mean age
at surgery was 14.0 (range 3.9–42) years, mean body
weight was 45.7 (range 15.5–90) kg. Five patients had the
clinical diagnosis of CPVT, three were genotype positive
for a mutation in the ryanodine-receptor-2-gene. Four of
five LQTS patients were genotype positive. Indications for
LCSD were recurrent syncope, symptomatic episodes of
ventricular tachycardias and/or internal cardioverter–defi-
brillator (ICD) discharges, and aborted cardiac arrest
despite high doses of beta-blockers.
Results LCSD was performed via the transaxillary
approach. No significant complications were observed.
Two patients already had an ICD, 6 patients received an
ICD at the same operation or shortly thereafter. Median
length of follow-up after LCSD was 2.3 (range 0.6–3.9)
years. After LCSD a marked reduction in arrhythmia bur-
den and cardiac events was observed in all patients while
medication was continued. None of the patients had any
further ICD discharge for sustained VT.
Conclusions After LCSD, arrhythmia burden could sig-
nificantly be reduced in all our young patients with CPVT
and LQTS.
Keywords CPVT  Long QT syndrome  Left cardiac
sympathetic denervation  Children and young adults
Abbreviations
CPVT Catecholaminergic polymorphic ventricular
tachycardia
ICD Internal cardioverter-defibrillator
LCSD Left cardiac sympathetic denervation
LQTS Long QT syndrome
VT Ventricular tachycardia
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channelopathies of genetic origin characterized by life-
threatening ventricular arrhythmias, which are triggered by
increased sympathetic activity, for example, physical
exercise and emotional stress. They often manifest at
young age, the first event may be fatal [1–6].
Therefore, in order to prevent cardiac events, the cor-
nerstone of medical treatment for patients with CPVT and
LQTS is beta-blocker pharmacotherapy [4–6]. However,
certain patients remain symptomatic despite high doses of
beta-blockers [7–10]. Particularly, 46–69 % of patients
with CPVT have been reported to continue to have cardiac
events [2]. In addition, some patients do not tolerate high-
dose beta-blockade. Finally, in teenage years poor com-
pliance with daily medication is known in patients with
chronic diseases and these patients often become symp-
tomatic again during this period of life. ICD implantation is
recommended in drug refractory, highly symptomatic cases
[11]. However, fatal failure of ICD therapy has been
reported [12] and frequent appropriate or inappropriate
ICD discharges as well as electrical storms are responsible
for significant morbidity and mortality and severely
decreased quality of life [13].
Left cardiac sympathetic denervation (LCSD) has been
suggested in this setting. Reports have documented its
efficacy for LQTS patients [14–17] and also in three small
case series for CPVT [16–18]. When performed appropri-
ately, LCSD is an antifibrillatory intervention that largely
prevents norepinephrine release in the heart without
reducing heart rate [19–24]. In the present report, we
describe our experience with LCSD for highly symptom-
atic young patients with LQTS and CPVT that were not
fully protected by beta-blocker therapy.
Patients and methods
Patients
All 10 patients who had been treated with LCSD at the
Children’s Heart Center Go¨ttingen between October 2007
and November 2011 were included. Medical chart review
was performed to obtain patient data, operative notes and
perioperative course as well as mid-term follow-up. Chart
review revealed five patients with the diagnosis of CPVT
and five patients with LQTS. Four patients diagnosed with
LQTS were tested positive for a mutation in the LQT 1-,
LQT 3-, and LQT 8-gene, respectively. In three patients
with CPVT a mutation in the RYR2-encoded cardiac
ryanodine receptor/calcium release channel had been
found. In the remaining two patients the results of genetic
testing were negative. All patients had a structurally nor-
mal heart and normal left ventricular function.
Indications for LCSD were severe symptoms not ade-
quately controlled by medical therapy including high-dose
beta-blockade in all patients. Cardiac events included
recurrent syncope, frequent non-sustained VT, sustained
VT with or without stress, repeated appropriate ICD
shocks/electric storm with multiple shocks, and aborted
cardiac arrest. An ICD had already been implanted before
LCSD in 2 patients, 6 patients received an ICD at the same
operation or shortly thereafter (Table 1).
Values of sympathetic activity were obtained from ECG
and Holter monitoring studies during the hospital stay
unless stated otherwise.
The study protocol had been approved by the institu-
tional scientific committee of the Heart Center Go¨ttingen.
Technique of surgical LCSD
The procedure was performed under general anesthesia in
all patients. For the transaxillary approach a small
approximately 3–4 cm wide incision was made just below
the axillary hair line. During preparation care was taken to
avoid injury to the lymphatic vessels. The pleural space
was opened and the lung was retracted anteriorly in a
fashion to allow exposure of the stellate and the second
ganglion. The stellate ganglion was freed from its bed and
the sympathetic chain could be followed down as far as the
4th–5th thoracic ganglion. The stellate ganglion was dis-
sected in two halves, thus separating the first thoracic part
from the inferior cervical part. The cephalic portion of the
stellate ganglion was thus preserved to prevent Horner
syndrome. Then the thoracic ganglia T2–T4/T5 and their
associated rami communicantes were removed. The dis-
sected material was sent to the pathology laboratory to
ensure that nerve and ganglia were removed. A chest tube
was inserted until the next morning.
Statistical analysis
Continuous data are expressed as mean value ± standard
deviation or median and range.
Results
Main findings
Mean age of the patients was 14 (range 3.9–42) years,
mean body weight 45.7 (range 15.5–90) kg. Seven patients
were male. Two patients already had an ICD implanted
prior to LCSD. Four patients received an ICD at the same
operation, an ICD was implanted shortly after LCSD in 2
patients (Table 1). In the two remaining patients, both with
LQTS type 1, parents opted against the recommendation of
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ICD implantation after discussion of potential benefits and
complications.
The median length of follow-up after the procedure was
2.3 years (range 0.6–3.9) years. All patients had significant
and persistent relief from their cardiac symptoms (Fig. 1).
Perioperative course
Hospital stay for patients who received LCSD varied
depending on the condition the patient was in when admitted
to our unit. The two patients after cardiac arrest had a pro-
longed hospital stay of 2.5 and 8 weeks unrelated to LCSD.
In the remaining 8 patients hospital stay ranged from 3 to
9 days. The patient that was hospitalized for 9 days had a
pneumothorax after transvenous ICD implantation. Two
other patients, one who also had ICD implant at the same
time as LCSD, had a small pleural effusion that resolved
spontaneously. In 7 of 10 patients we observed a mild
Horner syndrome directly after LCSD which had resolved in
all but one patient at the first follow-up visit. No major
complications were noted in any of our patients.
Outcome of patients with CPVT
All five patients with CPVT were continued on their
medication with beta-blockade. None of them had any
further appropriate ICD discharge since LCSD.
Patient 1 (Table 1) had the most dramatic improvement
after the procedure. Despite high-dose beta-blockade
(6 mg/kg propranolol), this boy continued to have frequent
episodes of sustained VT resulting in appropriate ICD
discharges. From the day of LCSD, while he was main-
tained on the same high dose of propranolol, these episodes
subsided (Fig. 2). After more than 2 years, however, when
he became incompliant with his medication, ICD telemetry
Table 1 Demographics, patient data and indication for left cardiac sympathetic denervation








Reason for LCSD ICD (yes/no) Follow-
up
(years)
1 M 12.4 47.9 CPVT Propranolol,
metoprolol










3 M 17.0 90.0 CPVT Metoprolol Recurrent VT Yes 2.3
4 M 9.3 41.8 CPVT Metoprolol Recurrent syncope Yes 0.9
5 F 12.2 40.8 CPVT Metoprolol Recurrent syncope, aborted cardiac arrest Yes, at time of
LCSD
0.45
6 M 15.9 46.0 LQT 8 Propranolol Recurrent VT, syncope, side effects of
medication
Yes, at time of
LCSD
1.2
7 F 16.3 58.0 LQT 3 Metoprolol Recurrent syncope and seizures, side
effects of medication
Yes, at time of
LCSD
4.3
8 M 4.1 16.1 LQT 1 Propranolol Recurrent syncope, seizures No 1.2
9 M 3.9 15.5 LQT 1 Propranolol Recurrent syncope No 0.7
10 M 5.9 18.6 LQTS Propranolol,
esmolol, lidocaine
Aborted cardiac arrest Yes, at time of
LCSD
0.6
Median 15 57 2.3
Mean 14.02 45.7 1.8
Range 3.9–42 15.5–90 0.6–3.9
CPVT catecholaminergic polymorphic VT, ICD internal cardioverter/defibrillator, LCSD left cardiac sympathetic denervation, LQTS long QT
syndrome, VT ventricular tachycardia
Fig. 1 Graph illustrating reduction in severe cardiac events within
our cohort. Severe cardiac events ranged from numerous VT episodes
and ICD discharges in the two patients who already had an ICD,
aborted cardiac arrest in 2 further patients, two recurrent seizures and
syncope despite beta-blocker therapy in the youngest patient before
left cardiac sympathetic denervation
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again exhibited frequent non-sustained VT episodes, which
resolved after resuming his prescribed medical regimen.
Patient 2 also had frequent ICD discharges while on
therapy with beta-blockade (60 mg nadolol) that slightly
decreased in number after addition of calcium channel
blockers [7–9], but did not subside. Exercise stress testing
performed before and shortly after LCSD showed signifi-
cantly decreased arrhythmia burden (Fig. 3). Since LSCD,
no further appropriate ICD discharge has occurred while
medications could slightly be tapered.
The third patient with CPVT was a 17-year-old boy,
who chose LCSD after recurrent episodes of syncope on
beta-blockers. Prior to LCSD and despite high-dose
metoprolol (150 mg) fast polymorphic VT could repro-
ducibly be induced during exercise stress tests. Repeat
exercise stress testing 3 days after LCSD showed marked
reduction in ventricular ectopy. Non-sustained VT episodes
are regularly recorded by the ICD and a near syncopal
event occurred. As he does not show for regular follow-up
visits, this event was attributed to non-compliance with his
medical regimen.
The fourth patient with CPVT, a 9-year-old boy, presented
with recurrent syncope during exercise despite high-dose
beta-blocker therapy. After LCSD he did not experience any
further syncope.
Finally, the fifth patient of this group was referred to our
institution after an aborted cardiac arrest while on meto-
prolol. Prior to this event, recurrent syncope with exercise
had occurred and exercise stress testing had documented an
increase in ventricular ectopy. For secondary prevention,
an ICD was implanted and LCSD performed. ICD telem-
etry has not shown any sustained or non-sustained episodes
of VT since LCSD.
Outcome of patients with LQTS
Following LCSD, no significant shortening of the QTc
interval could be observed in any of our LQTS patients
(Table 2).
This boy (patient #6, Table 1) had been followed for
cerebral seizures until the age of 6 years when LQTS was
diagnosed. Beta-blocker therapy was then initiated and a
mutation was found in the LQT 8-gene. Despite increasing
doses up to 5 mg/kg propranolol he continued to experi-
ence syncopal episodes followed by seizures. In addition,
he exhibited fatigue likely due to decreased heart rate und
hypotension as side effects of high-dose propranolol. At the
time of LCSD, an ICD was also implanted. Since then, no
further episodes of syncope have occurred while his dose
of propranolol could be tapered to 3 mg/kg per day. ICD
analysis during follow-up did not show any significant
episodes of ventricular ectopy.
A 16-year-old girl with LQT 3 still developed non-
sustained polymorphic VT during exercise stress testing
while on daily metoprolol (3 mg/kg). Since LCSD and
more than 3 years of follow-up, no syncope or ICD
Fig. 2 ICD recording of a 12-year-old boy with catecholaminergic
ventricular tachycardia with frequent ICD discharges: following left
cardiac sympathetic denervation in May 2008 (dotted line) a marked
reduction of episodes of ventricular tachycardia is evident. No further
ICD discharge has occurred up to date
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discharge occurred. ICD telemetry revealed only 2 short
non-sustained runs of VT in the last 6-month period.
Two patients (#8 and #9) had a mutation in the LQT 1
gene. These were the youngest patients within our group, 3
and 4 years of age, respectively. Both had recurrent syn-
copal episodes, one also with seizures, despite high doses
of propranolol (4 and 5 mg/kg per day, respectively). Since
LCSD, no syncope has occurred while both were continued
on the same medication as before. In each case, implan-
tation of an ICD was declined by the parents.
The last patient (#10) with LQTS, who was mutation
negative for LQT types 1–3, received LCSD at time of ICD
implantation for his second aborted cardiac arrest while on
beta-blocker therapy.
Sympathetic activity
None of our patients had a decrease in systolic blood
pressure or mean heart rate on Holter recording after
LCSD. The corrected QT interval (according to Bazett’s
formula) was normal in our CPVT patients before LCSD,
after the procedure it decreased in two and increased in
duration insignificantly in three patients. The corrected QT
interval in patients with LQTS decreased slightly but
remained abnormal in two patients, remained the same in
two patients and increased in one patient. The PR interval
exhibited a certain degree of variability with an increase up
to 20 ms and a decrease up to 15 ms within our patient
cohort. Using the standard deviation of all normal R–R
intervals of the Holter recording (SDNN) as a measure of
heart rate variability, we observed a decrease in all eight
patients in whom complete data were available. Two
patients had a low heart rate variability (\50 ms) after the
procedure, one had had a recent aborted cardiac arrest
(Patient #10) and the other had already shown a decreased
heart rate variability (\100 ms) before the procedure.
Heart rate variability with focus on the parasympathetic
branch showed also a decrease in the majority of our
patients but was clearly abnormal only in the patient after a
recent aborted cardiac arrest (Patient #10), for details
please see Table 2.
Discussion
Main findings
We report our experience of LCSD in nine children and
one young adult with diseases associated with significant
risk of sudden cardiac death, CPVT and LQTS. LCSD
decreased arrhythmia burden significantly in all patients,
but not all patients exhibited the same amount of benefit
(Fig. 1). Patient (#1, Table 1) with CPVT demonstrated the
most symptomatic improvement after LCSD but showed
recurrence of VT episodes during incompliance with his
beta-blocker therapy in adolescence. VT disappeared again
after resuming his high-dose regimen, and the positive
effects persist. ICD telemetry in the 17-year-old boy (#3,
Table 1) after a near syncopal event occasionally docu-
mented non-sustained episodes of VT. Similarly to patient
Fig. 3 Six-lead electrocardiograms (ECGs) obtained from patient #2
during exercise stress testing before and 2 days after left cardiac
sympathetic denervation. a ECG at a work load of 80 W for 2 min:
frequent ventricular premature beats are present as ventricular
bigemini with 2 different morphologies. The test was terminated.
b Sinus rhythm is still present at 125 W for 3 and a half minutes
without any ventricular ectopy. The patient terminated the test at this
level due to muscular exhaustion
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#1, we assume that this adolescent was not compliant with
his medication because he also had not regularly shown for
scheduled follow-up visits. This implies that LCSD alone
may not be sufficient to completely suppress VT in certain
patients with CPVT. Therefore, in patients with CPVT the
same dose of beta-blockade should be maintained to avoid
recurrent symptoms.
On the other hand, in one of our patients with LQTS and
side effects of beta-blocker therapy, medication could be
reduced after LCSD. No cardiac events and no significant
VT episodes on ICD interrogation have been noted in the
follow-up period. This underscores that dosage of beta-
blockers has to be chosen on an individual basis for the
personalized medicine requirements of patients with LQTS
and CPVT [17, 25–28].
Several small studies have suggested that a more car-
dioselective beta-blocker, such as atenolol, may be less
efficacious than non-selective beta-blockers such as pro-
pranolol and nadolol in treatment of symptomatic patients
with LQTS [29]. Patients with LQT1 benefit the most from
beta-blocker therapy when compared to those with LQT2
and LQT3. One study showed that only 10 % LQT1 of
patients had breakthrough symptoms while 23 % of LQT2
and 32 % of LQT3 patients had breakthrough [30]. Con-
troversy exists for treatment of LQT3 with beta-blockers as
they may be potentially proarrhythmic because of con-
comitant slowing of heart rate. As LCSD has been shown
not to decrease heart rate [19–24], as also observed in our
small cohort, LCSD may be a particular good option in
patients with LQT3. Among genotyped LQTS patients,
LCSD tended to be significantly more effective in patients
with LQT1 and LQT3 [15].
Surgical technique
A minimally invasive approach, video-assisted thoraco-
scopic cardiac denervation, has recently been described in
two case series [16, 17]. This technique offers a smaller
operative trauma than the open surgical transaxillary
approach [31] as used in our institution. An open surgical
approach via supraclavicular exposure [32] has been
applied in the largest series published by Schwartz et al.
[15] without major complications.
The transaxillary approach [31] leads to a good exposure
of the sympathetic trunk, intercostal and subclavian arteries,
the thoracic duct and phrenic nerve. In particular, it allows
good control of accidental bleeding from the intercostal
vessels while life-threatening great vessel injury is rare.
Especially in infants, small children or patients with a short
neck, the transaxillary approach may be a good surgical
option versus the thoracoscopic approach [16, 17, 31–33].
No significant complications were noted in the imme-
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which may include an electrical storm [16]. In most of our
patients incomplete Horner syndrome was observed tran-
siently, likely due to compression and swelling of the upper
half of the stellate ganglion. In 9/10 patients unilateral
Horner syndrome had disappeared at last follow-up. Neu-
rologic symptoms, such as neuralgia and sharp arm pain
[32], or harlequin facial flushing up to several years [16],
were not observed in our patient group.
Nevertheless, no matter which technique of LCSD was
used, perioperative complications were minor and signifi-
cant symptomatic relief for the affected patients after
LCSD has uniformly been observed.
Recently, beneficial effects of catheter-based renal
sympathetic denervation for the treatment of patients with
heart failure and malignant tachyarrhythmias have been
reported. This new, still experimental approach might offer
the opportunity to achieve reduction of the cardiac sym-
pathetic activity even without an operation [34].
Management approach in CPVT patients
As experience of LCSD in CPVT patients is limited, and a
new treatment option with flecainide has been reported
recently, these patients deserve additional comments.
In our small cohort of patients with CPVT, LCSD was
very effective in preventing new life-threatening tachy-
cardia events. In the past, calcium channel blocking agents
have been used in patients with ineffective b-blocker
therapy [7–9]. However, in subsequent reports calcium
channel blocking agents were not consistently effective in
preventing sudden cardiac death in CPVT patients [7, 35,
36]. It is of note that also two of our patients had been
treated unsuccessfully with verapamil.
Flecainide has been reported recently in a multicenter
case series to be effective in 75 % of the patients to reduce
exercise-induced ventricular arrhythmias [37]. A plausible
molecular mechanism and an animal model support its
potential as a useful drug in CPVT [38, 39]. It has been
suggested that flecainide in addition to beta-blocker ther-
apy should be considered for CPVT patients who otherwise
have few alternative therapeutic options. Although data
seem very promising, as number of patients and mean
follow-up were limited to 20 months, these findings need
to be validated in a larger group of patients with a pro-
longed follow-up.
It may be speculated that some patients with CVPT and
persistent symptoms under beta-blocker therapy will ben-
efit from flecainide without the need of LCSD. It is of note,
however, that medical therapy will only be effective as
long as the patients adhere to strict regular drug intake with
an effective dose. An appropriate ICD discharge was
observed in one patient who had a low flecainide level in
the study reported by van der Werf et al. [37]. As with any
oral medication, the problems of regular intake and poor
compliance are still of paramount importance. In addition,
a sufficient dose of flecainide has to be achieved with the
potential of side effects as this drug has a relatively narrow
therapeutic range. Finally, one has to keep in mind, that in
case of treatment failure, the first event may be fatal.
Depending on the individual situation of the patient, fle-
cainide in addition to beta-blocker therapy alone may not
be safe in every patient to prevent syncope and sudden
cardiac death. Therefore, we think, that LCSD should be
offered to young patients with CPVT who are not suffi-
ciently protected by medical therapy.
Outlook
LCSD is shown to be beneficial for highly symptomatic
patients with CPVT and LQTS. Despite these favorable
results [40], LCSD has not yet found its place in routine or
escalating care of patients with drug refractory LQTS and
CPVT [41, 42]. Schwartz [25] has recently proposed that
LCSD may even alter the necessity of ICD implantation in
selected patients, in particular LQT 1 patients [26], who
currently meet the class I indication for ICD implantation
as adverse events after ICD implantation have been
reported to be as high as 25 % in young patients [13].
In addition, in patients with CPVT not sufficiently
protected by medical therapy with an indication for ICD
implantation, combined LCSD at time of ICD implant [25]
has the potential to prevent ICD discharges. In this special
group of patients the first ICD shock—appropriate or not—
may trigger a sympathetic surge with subsequent shocks or
even an electrical storm.
Limitations
Limitations of this study are due to the inherent nature of a
retrospective design involving a limited patient number
secondary to the rare prevalence of these diseases. Quan-
titative marker of arrhythmia burden has been difficult to
express in statistically comparable data due to the large
variability in presenting symptoms. While benefits of
LCSD for LQTS patients have been described in long-term
follow-up [15], particular interest belongs to the short- and
long-term outcome of patients with CPVT, as to our
knowledge, our reports adds 5 more patients, up to a total
number of 27 patients published yet, in whom LCSD uni-
formly has been performed successfully to diminish sig-
nificant arrhythmogenic cardiac events and appropriate
ICD discharges ([16–18, 25, 43–46]; Table 3). Data from a
larger number of patients are needed to further assess the
effects of LCSD for CPVT and LQTS patients.
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Conclusion
LCSD via the transaxillary approach could safely be per-
formed with only minimal acute and long-term complica-
tions. LCSD effectively decreased the arrhythmia burden in
children and young adults with CPVT and LQTS. In par-
ticular, LCSD decreased appropriate ICD discharges in
patients with CPVT.
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